Slow controlled released combsn. preparation of semisolid framework of containing glipizide

A technology of glipizide and semi-solid, which is applied in the field of sustained and controlled release semi-solid matrix preparation composition, which can solve the problems of frequent administration, inability to release drug stably for a long time, and high incidence of toxic and side effects

Inactive Publication Date: 2007-10-24
SHANGHAI INST OF PHARMA IND CO LTD
View PDF1 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0011] The technical problem to be solved in the present invention is to disclose a slow and controlled release semi-solid matrix preparation composition containing glipizide, so as to overcome the problems in the prior art that the drug cannot be released stably for a long time in the body, the number of administrations is high, and the side effects High-incidence conditions to improve patient safety and compliance

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Slow controlled released combsn. preparation of semisolid framework of containing glipizide
  • Slow controlled released combsn. preparation of semisolid framework of containing glipizide
  • Slow controlled released combsn. preparation of semisolid framework of containing glipizide

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0044] 329g of macrogol glyceride stearate and 141g of glyceryl behenate, heat and melt at 80°C, add 5g of glipizide, stir to mix evenly, cool to 60-70°C and fill with capsule liquid Machine filling in No. 1 capsules to make 1000 capsules. The in vitro release curve is shown in Figure 3. (Release 24H)

Embodiment 2

[0046] Glipizide 5, palmitic acid 200g, glyceryl behenate 150g, beeswax 150g, grind until fully dissolved, mix well and heat to 80°C, stir to mix evenly, cool to 60-70°C and use capsule liquid filling machine Fill in No. 1 capsules to obtain 1000 capsules. The in vitro release curve is shown in Figure 4. (release 24H)

Embodiment 3

[0048] 103.4g of macrogol glyceride stearate, 117.5g of carnauba wax, heat and melt at 80°C, add 5g of glipizide, 4.7g of ethyl cellulose (10CP), stir to make the mixture uniform, and slowly add 239.7 g of soybean oil, after mixing, was cooled to 60-70 DEG C and filled in No. 1 capsules with a capsule liquid filling machine to obtain 1000 capsules. The in vitro release curve is shown in Figure 5. (release 24H)

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

A slowly-or controllably-releasing semi-solid medicine for treating diabetes B is proportionally prepared from glipizide and slowly-releasing semi-solid skeleton carrier.

Description

technical field [0001] The invention relates to a sustained and controlled release semi-solid matrix preparation composition containing glipizide. Background technique [0002] Glipizide, white, odorless and tasteless, insoluble in water and ethanol, pKa is 5.9. Its English name is Glipizide, and its chemical name is 1-cyclohexyl-3-{4-[2-(5-methylpyrazine-2-amide)-ethyl]benzenesulfonyl}urea. Its structural formula is as follows: [0003] [0004] Molecular formula: C 21 h 27 N 5 o 4 S, molecular weight: 445.54 [0005] Glipizide is a second-generation sulfonylurea oral hypoglycemic drug, which can promote the secretion of insulin by pancreatic β cells and enhance the effect of insulin on target tissues; it can also stimulate pancreatic α cells to inhibit glucagon secretion. Inhibit liver glycogen breakdown, promote muscle utilization and consumption of glucose. Clinically, it is mainly used for patients with mild to moderate non-insulin-dependent diabetes mellitus...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/4965A61K9/48A61K9/20A61P3/10
Inventor 顾林金赵晓群沈航孝陆伟根
Owner SHANGHAI INST OF PHARMA IND CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap